Erasca (ERAS) said Tuesday it is pursuing partnership opportunities for naporafenib to extend its cash runway to the second half of 2028 from the second half of 2027.
Erasca also said the US Food and Drug Administration has cleared its investigational new drug application of ERAS-0015 for patients with RAS-mutant solid tumors.
The company said it has also submitted an investigational new drug application for ERAS-4001, a potential first-in-class pan-KRAS inhibitor in KRAS-mutant solid tumors.
Erasca said it expects phase 1 monotherapy data from both programs in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.